{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:55:58Z","timestamp":1785030958022,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.4065\/mcp.2009.0503","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T02:06:14Z","timestamp":1262829974000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update"],"prefix":"10.4065","volume":"85","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.4065\/mcp.2009.0503_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.2008.78.702","article-title":"Eosinophilia among returning travelers: a practical approach","volume":"78","author":"Meltzer","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.4065\/mcp.2009.0503_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-4632.2008.03637.x","article-title":"Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review","volume":"47","author":"Ganeva","year":"2008","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.4065\/mcp.2009.0503_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1590\/S1806-37132009000600010","article-title":"Pulmonary eosinophilia","volume":"35","author":"Campos","year":"2009","journal-title":"J Bras Pneumol"},{"issue":"11","key":"10.4065\/mcp.2009.0503_bib5","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1007\/s10620-005-9011-2","article-title":"Eosinophilic gastroenteritis: a review","volume":"52","author":"M\u00e9ndez-S\u00e1nchez","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.4065\/mcp.2009.0503_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0025-6196(11)61101-4","article-title":"Eosinophilic esophagitis: is it all allergies?","volume":"82","author":"Swoger","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/mcp.2009.0503_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/499238","article-title":"Diagnostic evaluation of newly arrived asymptomatic refugees with eosinophilia","volume":"42","author":"Seybolt","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0025-6196(11)60972-5","article-title":"33-year-old woman with marked eosinophilia","volume":"82","author":"Lassmann","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.4065\/mcp.2009.0503_bib10","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib11","first-page":"497","article-title":"Hypereosinophilic syndrome and cyclic oscillations in blood cell counts: a clonal disorder of hematopoiesis originating in a pluripotent stem cell","volume":"89","author":"Malcovati","year":"2004","journal-title":"Haematologica"},{"issue":"10","key":"10.4065\/mcp.2009.0503_bib12","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007611-198910000-00028","article-title":"Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas","volume":"82","author":"Brown","year":"1989","journal-title":"South Med J"},{"issue":"11","key":"10.4065\/mcp.2009.0503_bib13","first-page":"1489","article-title":"Transition of the hypereosinophilic syndrome to myelomonocytic leukemia","volume":"121","author":"Owen","year":"1979","journal-title":"Can Med Assoc J"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0165-4608(84)90018-9","article-title":"Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome","volume":"11","author":"Yoo","year":"1984","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"10.4065\/mcp.2009.0503_bib15","first-page":"149","article-title":"Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation","volume":"4","author":"Needleman","year":"1990","journal-title":"Hematol Pathol"},{"issue":"13","key":"10.4065\/mcp.2009.0503_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.4065\/mcp.2009.0503_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.beha.2005.07.010","article-title":"Pathogenesis, clinical features, and treatment advances in mastocytosis","volume":"19","author":"Pardanani","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"issue":"3","key":"10.4065\/mcp.2009.0503_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2009.07599.x","article-title":"The hypereosinophilic syndromes: current concepts and treatments","volume":"145","author":"Gleich","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2169\/internalmedicine.39.350","article-title":"Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder [letter]","volume":"39","author":"Sato","year":"2000","journal-title":"Intern Med"},{"issue":"9","key":"10.4065\/mcp.2009.0503_bib22","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes [letter]","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9149(00)00841-9","article-title":"Clinical and echocardiographic features of hypereosinophilic syndromes","volume":"86","author":"Ommen","year":"2000","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9343(03)00475-3","article-title":"Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib [letter]","volume":"115","author":"Koury","year":"2003","journal-title":"Am J Med"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.euje.2004.02.006","article-title":"Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor","volume":"5","author":"Ascione","year":"2004","journal-title":"Eur J Echocardiogr"},{"issue":"10","key":"10.4065\/mcp.2009.0503_bib27","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cancergencyto.2004.01.013","article-title":"Prevalence, breakpoint distribution, and clinical correlates of t(5;12)","volume":"153","author":"Greipp","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","article-title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia","volume":"138","author":"Curtis","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.4065\/mcp.2009.0503_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.leukres.2008.11.016","article-title":"Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1\/PDGFRA fusion and PDGFRA translocations","volume":"33","author":"Fink","year":"2009","journal-title":"Leuk Res"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib32","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2141.2008.07546.x","article-title":"Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up","volume":"145","author":"Helbig","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.4065\/mcp.2009.0503_bib35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR\u03b1-positive hypereosinophilic syndrome: results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.4065\/mcp.2009.0503_bib36","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2009.0503_bib37","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFR\u03b1 D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGF T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002770050018","article-title":"Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration","volume":"79","author":"Sch\u00f6ffski","year":"2000","journal-title":"Ann Hematol"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1582-4934.2008.00559.x","article-title":"Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1","volume":"13","author":"Tefferi","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000140631","article-title":"Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders","volume":"119","author":"Cross","year":"2008","journal-title":"Acta Haematol"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib44","first-page":"651","article-title":"\u03b1IFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5)","volume":"84","author":"Luciano","year":"1999","journal-title":"Haematologica"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.1996.00298.x","article-title":"Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality","volume":"92","author":"Malbrain","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<137::AID-AJH9>3.0.CO;2-T","article-title":"Clinical and cytogenetic remission induced by interferon-\u03b1 in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation","volume":"58","author":"Yamada","year":"1998","journal-title":"Am J Hematol"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"issue":"9","key":"10.4065\/mcp.2009.0503_bib48","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"20","key":"10.4065\/mcp.2009.0503_bib49","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome [letter]","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.4065\/mcp.2009.0503_bib50","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.4065\/mcp.2009.0503_bib51","first-page":"383","article-title":"Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy","volume":"78","author":"Prin","year":"1989","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib53","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1084\/jem.167.5.1737","article-title":"Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 as an eosinophil chemotactic factor","volume":"167","author":"Yamaguchi","year":"1988","journal-title":"J Exp Med"},{"issue":"12","key":"10.4065\/mcp.2009.0503_bib54","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","article-title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils","volume":"88","author":"Elsner","year":"1996","journal-title":"Blood"},{"issue":"6","key":"10.4065\/mcp.2009.0503_bib55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.leukres.2008.10.004","article-title":"Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFR\u03b1 mutation status","volume":"33","author":"Jain","year":"2009","journal-title":"Leuk Res"},{"issue":"40","key":"10.4065\/mcp.2009.0503_bib56","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1055\/s-2004-831852","article-title":"Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib [in German]","volume":"129","author":"Wolf","year":"2004","journal-title":"Dtsch Med Wochenschr"},{"issue":"8","key":"10.4065\/mcp.2009.0503_bib57","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.leukres.2008.12.001","article-title":"Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFR\u03b1-negative hypereosinophilic syndrome","volume":"33","author":"Butterfield","year":"2009","journal-title":"Leuk Res"},{"issue":"12","key":"10.4065\/mcp.2009.0503_bib58","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab [published correction appears in N Engl J Med. 2008;358(23):2530]","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2009.0503_bib59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpeds.2009.01.058","article-title":"Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5","volume":"155","author":"Mehr","year":"2009","journal-title":"J Pediatr"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","author":"Verstovsek","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib61","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib62","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O'Brien","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib63","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2008.282","article-title":"Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy [letter]","volume":"23","author":"Hwang","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.4065\/mcp.2009.0503_bib64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bmt.1705437","article-title":"Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript [letter]","volume":"38","author":"Halaburda","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.4065\/mcp.2009.0503_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","author":"Ueno","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bmt.1703379","article-title":"Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome","volume":"29","author":"Juvonen","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib69","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML [letter]","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.4065\/mcp.2009.0503_bib70","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"7037","key":"10.4065\/mcp.2009.0503_bib71","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib72","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"10.4065\/mcp.2009.0503_bib73","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.4065\/mcp.2009.0503_bib74","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.4065\/mcp.2009.0503_bib75","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2402556","article-title":"Tyrosine kinase fusion genes in chronic myeloproliferative diseases","volume":"16","author":"Cross","year":"2002","journal-title":"Leukemia"},{"issue":"5","key":"10.4065\/mcp.2009.0503_bib76","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4065\/82.5.599","article-title":"Evaluation of \u201cincreased\u201d hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests","volume":"82","author":"Tefferi","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.4065\/mcp.2009.0503_bib77","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:13:10Z","timestamp":1710457990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611603893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0025619611603893"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2009.0503","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2009.0503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}